MedPath

Impact of Bridge™ Device to Treat Opioid Withdrawal Symptoms

Not Applicable
Terminated
Conditions
Opioid Use Disorder
Registration Number
NCT05924945
Lead Sponsor
Masimo Corporation
Brief Summary

The purpose of this prospective study is to investigate the efficacy of the Bridge™ device in reducing the symptoms of opioid withdrawal in a blind comparison to a sham device.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
13
Inclusion Criteria
  • Participant able to provide written informed consent
  • Participant is 18 to 65-years old
  • Participant has confirmed opioid use disorder (OUD) as defined by the Diagnostic and Statistical Manual of Mental Disorders-5
  • Participants is entering an OUD treatment program
Exclusion Criteria
  • Participant requires tapering from another substance at entry to treatment
  • Participant is pregnant or lactating
  • Participant has a history of hemophilia or psoriasis vulgaris
  • Participant has a cardiac pacemaker implant device
  • Participant has irritated or broken skin at the site of intended device placement
  • Participant is currently participating in, or was enrolled in another clinical trial within the last 30 days
  • Participant has a history of poor wound healing
  • Participant has a severe autoimmune disease or uncontrolled diabetes
  • Participant has an open wound/abscess infection/MRSA
  • Participant has a history of a chronic pain in the last 90 days
  • Participant has a serious medical condition which in the judgment of the principal investigator or his/her designee would make study participation unsafe, or would make intervention compliance difficult
  • Participant has a psychiatric illness (bipolar disorder, schizophrenia, or other psychotic disorder, active suicidal ideation with a plan within the last month or suicide attempt)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Assess Change in Clinical Opiate Withdrawal Scale (COWS) Scoreprior to device placement (0 min), 30 min, 60 min, 120 min, 2nd day, 3rd day, 4th day and 5th day of continuous device use

The Clinical Opiate Withdrawal Scale (COWS) is an 11-item scale designed to be administered by a clinician. This tool can be used in both inpatient and outpatient settings to reproducibly rate common signs and symptoms of opiate withdrawal and monitor these symptoms over time. The summed score for the complete scale can be used to help clinicians determine the stage or severity of opiate withdrawal and assess the level of physical dependence on opioids. Score Range: The COWS score can range from 0 to 48.

Interpretation:

0-4: No withdrawal 5-12: Mild withdrawal 13-24: Moderate withdrawal 25-36: Moderately severe withdrawal 37-48: Severe withdrawal High scores mean more severe withdrawal.

Secondary Outcome Measures
NameTimeMethod
Assess Change in Subjective Opiate Withdrawal Scale (SOWS) Scoreprior to device placement (0 min), 30 min, 60 min, 120 min, 2nd day, 3rd day, 4th day and 5th day of continuous device use

The Subjective Opiate Withdrawal Scale (SOWS) consist of 16 symptoms rated in intensity by patients on a 5-point scale of intensity as follows: 0=not at all, 1=a little, 2=moderately, 3=quite a bit, 4=extremely. The total score is a sum of item ratings, and ranges from 0 to 64.

High scores mean worse symptom intensity.

Trial Locations

Locations (1)

Caron Treatment Centers

🇺🇸

Wernersville, Pennsylvania, United States

Caron Treatment Centers
🇺🇸Wernersville, Pennsylvania, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.